Agios Exec Sells Shares, But Overall Stake Grows
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Viswanadhan Krishnan, Agios Pharmaceuticals CSO, sold a third of his vested shares, totaling $82,000, on his work anniversary. Despite reducing direct ownership, his overall stake grows due to unvested units and new grants. Agios revenue surges with PYRUKYNDs success, and they aim for FDA approval in sickle cell disease. This sale appears routine, not a cause for concern, as Agios strengthens its position in the market.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/648419d1e2d91d02